Shailesh K. Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shailesh K. Gupta has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Anny M. S. Cheng
Department of Ophthalmology, University of Florida , 6201 W Newberry Rd, Gainesville, FL 32605
6 shared publications - Kakarla Venkata Chalam
Department of Ophthalmology, Loma Linda University , 11370 Anderson St., Suite 1800, Loma Linda, CA 92354
3 shared publications Anny M. Cheng
Ophthalmology, Broward Health, Fort Lauderdale, USA
2 shared publications- David T. Y. Yang
College of Biological Science, University of California, Davis, Sacramento, CA 95616, USA
2 shared publications - Jineel Bhatt
Specialty Retina Center, Coral Springs, FL 33067, USA
2 shared publications Joby Tsai
Ophthalmology, Broward Health, Fort Lauderdale, USA
2 shared publications
Latest Publications
- Open Access
- 18 February 2026
- Published by Edorium Journals Pvt. Ltd.
- Vol. 9 (1) , 6-10
Multimodal imaging in a case of acute erdafitinib-induced maculopathy
Introduction: To analyze multimodal imaging findings in a patient with erdafitinib-induced maculopathy. Case Report: An 80-year-old male presented to our retina clinic with decreased vision in his left eye that began two weeks prior to his most recent visit. His past ocular history included epiretinal membranes in both eyes. He had been diagnosed with bladder cancer and had been undergoing aggressive chemotherapy, which was discontinued two months prior to this visit due to serious adverse effects. One month before the most recent visit, his oncologist had initiated treatment with erdafitinib. His best corrected visual acuity was 20/50 in the right eye and 20/100 in the left eye. Fundus examination revealed macular pucker, mild diabetic retinopathy, and mild hypertensive retinopathy in both eyes. Optical coherence tomography imaging of the macula showed new onset subretinal fluid in both eyes. Fluorescein angiography and indocyanine green angiography of the retina and choroid did not show any abnormalities explaining the subretinal fluid. Conclusion: Erdafitinib can cause toxic maculopathy with subretinal fluid on optical coherence tomography of the retina with no abnormalities on fluorescein angiography and indocyanine green angiography.
- 18 February 2026
- Published by Edorium Journals Pvt. Ltd.
- Vol. 9 (1) , 6-10
Open AccessMultimodal imaging in a case of acute erdafitinib-induced maculopathy
Introduction: To analyze multimodal imaging findings in a patient with erdafitinib-induced maculopathy. Case Report: An 80-year-old male presented to our retina clinic with decreased vision in his left eye that began two weeks prior to his most recent visit. His past ocular history included epiretinal membranes in both eyes. He had been diagnosed with bladder cancer and had been undergoing aggressive chemotherapy, which was discontinued two months prior to this visit due to serious adverse effects. One month before the most recent visit, his oncologist had initiated treatment with erdafitinib. His best corrected visual acuity was 20/50 in the right eye and 20/100 in the left eye. Fundus examination revealed macular pucker, mild diabetic retinopathy, and mild hypertensive retinopathy in both eyes. Optical coherence tomography imaging of the macula showed new onset subretinal fluid in both eyes. Fluorescein angiography and indocyanine green angiography of the retina and choroid did not show any abnormalities explaining the subretinal fluid. Conclusion: Erdafitinib can cause toxic maculopathy with subretinal fluid on optical coherence tomography of the retina with no abnormalities on fluorescein angiography and indocyanine green angiography.
- Open Access
- 14 March 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-8
Macular hole repair using a refined viscoelastic assisted membrane positioning technique markedly improves surgical success rates
Introduction: To evaluate the surgical outcomes of pars plana vitrectomy (PPV) using dispersive viscoelastic-assisted inverted internal limiting membrane (VILM) flap technique in patients with full-thickness macular holes (MH). Methods: We retrospectively review 247 eyes that underwent PPV with the VILM flap technique and had a minimum follow-up of six months. Following core vitrectomy, the internal limiting membrane (ILM), stained with indocyanine green, was placed on the MH. A dispersive viscosurgical device was applied over the ILM flat to secure its placement before fluid-gas exchange. Sulfur hexafluoride gas was used for tamponade, and patients maintained face-down positioning postoperatively. The primary outcomes assessed were anatomical closure of MH at 90 days confirmed with optical coherence tomography and changes in best-corrected visual acuity (BCVA). Results: Anatomical closure of MH was achieved in 98% of eyes at 90 days postoperatively. Success rates were inversely correlated with MH diameter: 100% for small (< 400 μm; n = 122), 98% for medium (400–800 μm; n = 102), and 91.3% for large (> 800 μm; n = 23) holes. The median improvement in BCVA was 0.3 logMAR. Significant improvement in BCVA was observed at three months (p = 0.025) and six months ( p = 0.019) postoperatively. Final BCVA improved in 87% of eyes (n = 215), remained stable in 11% (n = 27), and worsened in 2% (n = 5). No cases of ILM flap displacement were noted. Conclusion: The VILM flap technique during PPV is highly effective for treating MH, demonstrating high anatomical closure rates and significant visual improvement. This method enhances the likelihood of successful outcomes after initial surgery.
- 14 March 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-8
Open AccessMacular hole repair using a refined viscoelastic assisted membrane positioning technique markedly improves surgical success rates
Introduction: To evaluate the surgical outcomes of pars plana vitrectomy (PPV) using dispersive viscoelastic-assisted inverted internal limiting membrane (VILM) flap technique in patients with full-thickness macular holes (MH). Methods: We retrospectively review 247 eyes that underwent PPV with the VILM flap technique and had a minimum follow-up of six months. Following core vitrectomy, the internal limiting membrane (ILM), stained with indocyanine green, was placed on the MH. A dispersive viscosurgical device was applied over the ILM flat to secure its placement before fluid-gas exchange. Sulfur hexafluoride gas was used for tamponade, and patients maintained face-down positioning postoperatively. The primary outcomes assessed were anatomical closure of MH at 90 days confirmed with optical coherence tomography and changes in best-corrected visual acuity (BCVA). Results: Anatomical closure of MH was achieved in 98% of eyes at 90 days postoperatively. Success rates were inversely correlated with MH diameter: 100% for small (< 400 μm; n = 122), 98% for medium (400–800 μm; n = 102), and 91.3% for large (> 800 μm; n = 23) holes. The median improvement in BCVA was 0.3 logMAR. Significant improvement in BCVA was observed at three months (p = 0.025) and six months ( p = 0.019) postoperatively. Final BCVA improved in 87% of eyes (n = 215), remained stable in 11% (n = 27), and worsened in 2% (n = 5). No cases of ILM flap displacement were noted. Conclusion: The VILM flap technique during PPV is highly effective for treating MH, demonstrating high anatomical closure rates and significant visual improvement. This method enhances the likelihood of successful outcomes after initial surgery.
- Open Access
- 1 January 2025
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 16 (1) , 521-527
Repeat Intravitreal Bevacizumab in a Very Low Birth Weight Infant with Recurrent ROP: 3-Year Follow-Up and Literature Review
Introduction: Low gestational birth weight is associated with increased incidence of retinopathy of prematurity (ROP). In recent years, intravitreal injection of anti-vascular endothelial growth factor (VEGF) has become more prevalent for ROP. Despite the demonstrated effectiveness following anti-VEGF injection, recurrence of ROP has been reported. A standardized treatment protocol for recurrent ROP following anti-VEGF monotherapy is still lacking, particularly for extremely low birth weight infants. This study reviews possible treatments for recurrent ROP and associated challenges. Case Presentation: We report a very low birth weight infant (500 g) with a recurrence of ROP after the initial intravitreal bevacizumab (IVB) injection, who was successfully treated with a repeat injection at a later date. No retinal detachment or recurrence was observed after a long-term follow-up of 36 months. Conclusion: This case report highlights the complexity of managing ROP, particularly for recurrent ROP in very low birth weight infants. Premature infants with extremely low birth weight may benefit from a repeat injection of anti-VEGF after the initial IVB to treat the recurrence.
- 1 January 2025
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 16 (1) , 521-527
Open AccessRepeat Intravitreal Bevacizumab in a Very Low Birth Weight Infant with Recurrent ROP: 3-Year Follow-Up and Literature Review
Introduction: Low gestational birth weight is associated with increased incidence of retinopathy of prematurity (ROP). In recent years, intravitreal injection of anti-vascular endothelial growth factor (VEGF) has become more prevalent for ROP. Despite the demonstrated effectiveness following anti-VEGF injection, recurrence of ROP has been reported. A standardized treatment protocol for recurrent ROP following anti-VEGF monotherapy is still lacking, particularly for extremely low birth weight infants. This study reviews possible treatments for recurrent ROP and associated challenges. Case Presentation: We report a very low birth weight infant (500 g) with a recurrence of ROP after the initial intravitreal bevacizumab (IVB) injection, who was successfully treated with a repeat injection at a later date. No retinal detachment or recurrence was observed after a long-term follow-up of 36 months. Conclusion: This case report highlights the complexity of managing ROP, particularly for recurrent ROP in very low birth weight infants. Premature infants with extremely low birth weight may benefit from a repeat injection of anti-VEGF after the initial IVB to treat the recurrence.
- Open Access
- 14 August 2024
- Published by Springer Nature in Cureus
- Vol. 16 (8) , e66872
Dr. Scheffer C.G. Tseng: A Pioneer in Cryopreserved Amniotic Membrane for Regenerative Medicine
Dr. Scheffer Chuei-Goong Tseng is widely recognized as a pioneer in the development and application of cryopreserved amniotic membrane therapy. Dr. Tseng has completely revolutionized the management of ocular and various diseases through the success in the study of regenerative medicine, specifically through the human amniotic membrane. He has turned innovative scientific discoveries into products that contribute to many medical fields, including ophthalmology, orthopedics, oral and maxillofacial surgery, dermatology, and wound care. This review article explores Dr. Tseng’s background, career, and significant contributions to regenerative medicine, with a particular focus on the impact of cryopreserved amniotic membrane technology.
- 14 August 2024
- Published by Springer Nature in Cureus
- Vol. 16 (8) , e66872
Open AccessDr. Scheffer C.G. Tseng: A Pioneer in Cryopreserved Amniotic Membrane for Regenerative Medicine
Dr. Scheffer Chuei-Goong Tseng is widely recognized as a pioneer in the development and application of cryopreserved amniotic membrane therapy. Dr. Tseng has completely revolutionized the management of ocular and various diseases through the success in the study of regenerative medicine, specifically through the human amniotic membrane. He has turned innovative scientific discoveries into products that contribute to many medical fields, including ophthalmology, orthopedics, oral and maxillofacial surgery, dermatology, and wound care. This review article explores Dr. Tseng’s background, career, and significant contributions to regenerative medicine, with a particular focus on the impact of cryopreserved amniotic membrane technology.
- Open Access
- 20 May 2024
- Published by Springer Nature in Cureus
- Vol. 16 (5) , e60706
Decreased Ocular Perfusion Pressure Associated With Reverse Ophthalmic Artery Flow on Transcranial Doppler Ultrasonography
Innovative applications of clinical ocular diagnostic tools are emerging to help identify systemic disorders that extend beyond ocular diseases. Ophthalmodynamometry (ODM) is a screening tool that non-invasively determines mean central retinal artery pressure (MCRAP) and ocular perfusion pressure (OPP). Decreased OPP and MCRAP on Falck Medical Multifunctional Device (FMD, Falck Medical, Inc., Mystic, CT), along with reverse ophthalmic artery flow (ROAF) on transcranial Doppler ultrasonography (TCD), indicate increased collateral brain perfusion and possible stenosis of the ophthalmic artery or internal carotid artery (ICA). In this case report, we describe the case of a 78-year-old female with ROAF, reduced MCRAP, and OPP in the right eye, confirmed by carotid duplex of 50-79% right ICA stenosis. Early application of ODM and TCD allowed for prompt diagnosis and management with a vascular specialist.
- 20 May 2024
- Published by Springer Nature in Cureus
- Vol. 16 (5) , e60706
Open AccessDecreased Ocular Perfusion Pressure Associated With Reverse Ophthalmic Artery Flow on Transcranial Doppler Ultrasonography
Innovative applications of clinical ocular diagnostic tools are emerging to help identify systemic disorders that extend beyond ocular diseases. Ophthalmodynamometry (ODM) is a screening tool that non-invasively determines mean central retinal artery pressure (MCRAP) and ocular perfusion pressure (OPP). Decreased OPP and MCRAP on Falck Medical Multifunctional Device (FMD, Falck Medical, Inc., Mystic, CT), along with reverse ophthalmic artery flow (ROAF) on transcranial Doppler ultrasonography (TCD), indicate increased collateral brain perfusion and possible stenosis of the ophthalmic artery or internal carotid artery (ICA). In this case report, we describe the case of a 78-year-old female with ROAF, reduced MCRAP, and OPP in the right eye, confirmed by carotid duplex of 50-79% right ICA stenosis. Early application of ODM and TCD allowed for prompt diagnosis and management with a vascular specialist.
- Open Access
- 30 March 2024
- Published by Jaypee Brothers Medical Publishing in Journal of Current Glaucoma Practice
- Vol. 18 (1) , 28-30
Urrets–Zavalia Syndrome of Unresolving Mydriasis Following Endocyclophotocoagulation Combined with Phacoemulsification
Combined endocyclophotocoagulation and phacoemulsification (ECP/Phaco) are uncommonly associated with complications. We present the first case of a rare complication following ECP/Phaco. A 72-year-old patient with dense nuclear sclerotic cataracts and primary open-angle glaucoma (POAG) underwent bilateral surgery uneventfully. He experienced a brief episode of postoperative elevated intraocular pressure (IOP), but only one eye with a lower baseline IOP developed a dilated pupil. No pupillary response was observed after applying 4% pilocarpine. The fixed mydriasis persisted without reaction to light or near stimulus, and the best-corrected vision (BCVA) was 20/30 in the affected eye. This case reports a possible rare complication when undergoing ECP/Phaco therapy. The pathogenesis of Urrets–Zavalia syndrome is unknown, but we hypothesized that eyes with more pronounced increases in IOP from baseline may be more susceptible to ischemic injury to the pupillary sphincter, resulting in a chronically dilated pupil. Even a modest transient rise in postoperative IOP in a glaucomatous eye with normal baseline IOP could result in a chronically dilated pupil. Cheng AMS, Vedula GG, Kubal AA, et al. Urrets–Zavalia Syndrome of Unresolving Mydriasis Following Endocyclophotocoagulation Combined with Phacoemulsification. J Curr Glaucoma Pract 2024;18(1):28–30.
- 30 March 2024
- Published by Jaypee Brothers Medical Publishing in Journal of Current Glaucoma Practice
- Vol. 18 (1) , 28-30
Open AccessUrrets–Zavalia Syndrome of Unresolving Mydriasis Following Endocyclophotocoagulation Combined with Phacoemulsification
Combined endocyclophotocoagulation and phacoemulsification (ECP/Phaco) are uncommonly associated with complications. We present the first case of a rare complication following ECP/Phaco. A 72-year-old patient with dense nuclear sclerotic cataracts and primary open-angle glaucoma (POAG) underwent bilateral surgery uneventfully. He experienced a brief episode of postoperative elevated intraocular pressure (IOP), but only one eye with a lower baseline IOP developed a dilated pupil. No pupillary response was observed after applying 4% pilocarpine. The fixed mydriasis persisted without reaction to light or near stimulus, and the best-corrected vision (BCVA) was 20/30 in the affected eye. This case reports a possible rare complication when undergoing ECP/Phaco therapy. The pathogenesis of Urrets–Zavalia syndrome is unknown, but we hypothesized that eyes with more pronounced increases in IOP from baseline may be more susceptible to ischemic injury to the pupillary sphincter, resulting in a chronically dilated pupil. Even a modest transient rise in postoperative IOP in a glaucomatous eye with normal baseline IOP could result in a chronically dilated pupil. Cheng AMS, Vedula GG, Kubal AA, et al. Urrets–Zavalia Syndrome of Unresolving Mydriasis Following Endocyclophotocoagulation Combined with Phacoemulsification. J Curr Glaucoma Pract 2024;18(1):28–30.
- Open Access
- 10 December 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (24) , 3635
Recent Advances in Imaging Macular Atrophy for Late-Stage Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a leading cause of blindness worldwide. In late-stage AMD, geographic atrophy (GA) of dry AMD or choroidal neovascularization (CNV) of neovascular AMD eventually results in macular atrophy (MA), leading to significant visual loss. Despite the development of innovative therapies, there are currently no established effective treatments for MA. As a result, early detection of MA is critical in identifying later central macular involvement throughout time. Accurate and early diagnosis is achieved through a combination of clinical examination and imaging techniques. Our review of the literature depicts advances in retinal imaging to identify biomarkers of progression and risk factors for late AMD. Imaging methods like fundus photography; dye-based angiography; fundus autofluorescence (FAF); near-infrared reflectance (NIR); optical coherence tomography (OCT); and optical coherence tomography angiography (OCTA) can be used to detect and monitor the progression of retinal atrophy. These evolving diverse imaging modalities optimize detection of pathologic anatomy and measurement of visual function; they may also contribute to the understanding of underlying mechanistic pathways, particularly the underlying MA changes in late AMD.
- 10 December 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (24) , 3635
Open AccessRecent Advances in Imaging Macular Atrophy for Late-Stage Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a leading cause of blindness worldwide. In late-stage AMD, geographic atrophy (GA) of dry AMD or choroidal neovascularization (CNV) of neovascular AMD eventually results in macular atrophy (MA), leading to significant visual loss. Despite the development of innovative therapies, there are currently no established effective treatments for MA. As a result, early detection of MA is critical in identifying later central macular involvement throughout time. Accurate and early diagnosis is achieved through a combination of clinical examination and imaging techniques. Our review of the literature depicts advances in retinal imaging to identify biomarkers of progression and risk factors for late AMD. Imaging methods like fundus photography; dye-based angiography; fundus autofluorescence (FAF); near-infrared reflectance (NIR); optical coherence tomography (OCT); and optical coherence tomography angiography (OCTA) can be used to detect and monitor the progression of retinal atrophy. These evolving diverse imaging modalities optimize detection of pathologic anatomy and measurement of visual function; they may also contribute to the understanding of underlying mechanistic pathways, particularly the underlying MA changes in late AMD.
- Open Access
- 4 October 2023
- Published by MDPI AG in Preprints.org
Recent Advances on Imaging for Late-Stage Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a leading cause of blindness worldwide. In late-stage AMD, geographic atrophy (GA) of dry AMD or choroidal neovascularization (CNV) of neovascular AMD results in macular atrophy (MA), leading to significant visual loss. Despite the development of innovative therapies, there are currently no established effective treatments for MA. As a result, early detection of MA is critical in identifying later central macular involvement throughout time. Accurate and early diagnosis is achieved through a combination of clinical examination and imaging techniques. Our review of the literature depicted advances in retinal imaging to identify biomarkers of progression and risk factors for late AMD. Imaging methods like fundus autofluorescence (FAF), near-infrared reflectance (NIR), widefield imaging, optical coherence tomography (OCT), multicolor confocal scanning laser ophthalmoscopy (cSLO), and optical coherence tomography angiography (OCTA) can be used to detect and monitor the progression of retinal atrophy. Multifocal electroretinogram (ERG) and microperimetry are methods for quantifying visual function to map disease progression. The evolving diverse imaging modalities optimize detection of pathology anatomy and measurement of visual function; they may also contribute to the understanding of the underlying mechanistic pathways, particularly the underlying MA changes in late AMD.
- 4 October 2023
- Published by MDPI AG in Preprints.org
Open AccessRecent Advances on Imaging for Late-Stage Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a leading cause of blindness worldwide. In late-stage AMD, geographic atrophy (GA) of dry AMD or choroidal neovascularization (CNV) of neovascular AMD results in macular atrophy (MA), leading to significant visual loss. Despite the development of innovative therapies, there are currently no established effective treatments for MA. As a result, early detection of MA is critical in identifying later central macular involvement throughout time. Accurate and early diagnosis is achieved through a combination of clinical examination and imaging techniques. Our review of the literature depicted advances in retinal imaging to identify biomarkers of progression and risk factors for late AMD. Imaging methods like fundus autofluorescence (FAF), near-infrared reflectance (NIR), widefield imaging, optical coherence tomography (OCT), multicolor confocal scanning laser ophthalmoscopy (cSLO), and optical coherence tomography angiography (OCTA) can be used to detect and monitor the progression of retinal atrophy. Multifocal electroretinogram (ERG) and microperimetry are methods for quantifying visual function to map disease progression. The evolving diverse imaging modalities optimize detection of pathology anatomy and measurement of visual function; they may also contribute to the understanding of the underlying mechanistic pathways, particularly the underlying MA changes in late AMD.
- Open Access
- 1 July 2023
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 16, 419-423
Pituitary Macroadenoma with Optic Cupping Masquerading as Normal Tension Glaucoma
When non-glaucomatous disease with disc cupping mimics normal-tension glaucoma (NTG), diagnosis is challenging. The typical optic disc features of glaucomatous disease are often subjective, and often overlap with disc changes in compressive intracranial lesions. Ancillary diagnostic testing such as retinal nerve fiber layer (RNFL) analysis and visual field testing can elevate the index of suspicion of an underlying non-glaucomatous process. We present a case of a nonfunctional macroadenoma coexisting with NTG, although it is unclear if the concurrent brain lesion aggravated or caused it. This case highlights the diagnostic challenge of recognizing optic cupping and non-matching abnormalities in the visual field from a coexisting intracranial lesion, even in the absence of other neurological signs.
- 1 July 2023
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 16, 419-423
Open AccessPituitary Macroadenoma with Optic Cupping Masquerading as Normal Tension Glaucoma
When non-glaucomatous disease with disc cupping mimics normal-tension glaucoma (NTG), diagnosis is challenging. The typical optic disc features of glaucomatous disease are often subjective, and often overlap with disc changes in compressive intracranial lesions. Ancillary diagnostic testing such as retinal nerve fiber layer (RNFL) analysis and visual field testing can elevate the index of suspicion of an underlying non-glaucomatous process. We present a case of a nonfunctional macroadenoma coexisting with NTG, although it is unclear if the concurrent brain lesion aggravated or caused it. This case highlights the diagnostic challenge of recognizing optic cupping and non-matching abnormalities in the visual field from a coexisting intracranial lesion, even in the absence of other neurological signs.